利那洛肽

Linaclotide.

作者信息

Cada Dennis J, Levien Terri L, Baker Danial E

机构信息

Executive Editor, The Formulary.

Clinical Associate Professor of Pharmacotherapy, Drug Information Center, Washington State University, Spokane, Washington.

出版信息

Hosp Pharm. 2013 Feb;48(2):143-52. doi: 10.1310/hpj4802-143.

DOI:10.1310/hpj4802-143

PMID:24421452

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3839478/

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. Subscribers to The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The February 2013 monograph topics are tofacitinib, cabozantinib, suvorexant, vortioxetine, and apremilast. The DUE/MUE is on tofacitinib.

摘要

每月，《处方集专论服务》的订阅者会收到5至6篇关于新发布或处于3期临床试验后期的药物的详细专论。这些专论面向药学与治疗学委员会。订阅者每月还会收到1页关于对议程以及药学/护理在职培训有用的药物的简要专论。每月还会提供一份全面的目标药物利用评估/药物使用评估（DUE/MUE）。订阅后，专论将以印刷形式发送，也可在线获取。专论可进行定制以满足机构的需求。《处方集专论服务》的订阅者还可访问一个药学公告板——《处方集信息交流》（The F.I.X.）。所有与临床和医院药学相关的主题都会在The F.I.X.上进行讨论。现在每月会随《处方集专论服务》发布一份药物类别综述。通过与《处方集》的合作，《医院药学》在本专栏发表精选综述。有关《处方集专论服务》或The F.I.X.的更多信息，请致电《处方集》：800 - 322 - 4349。2013年2月的专论主题为托法替布、卡博替尼、苏沃雷生、伏硫西汀和阿普斯特。DUE/MUE的主题是托法替布。